Rocket Pharmaceuticals (RCKT) News Today

Company: Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT)

Shares of Rocket Pharmaceuticals have declined after the U.S. Food and Drug Administration placed a clinical hold on the company’s gene therapy trial following protocol changes. The halt has prompted a wave of securities class action lawsuits and firm investigations alleging that Rocket and certain officers misled investors. On the brighter side, Cantor Fitzgerald reiterated its “Overweight” rating and set a $30 target price, reflecting more optimistic FY2026 earnings estimates.

• Cantor Fitzgerald maintains an “Overweight” rating on RCKT with a $30 target price and forecasts FY2026 EPS of ($1.66), above the consensus of ($2.83).
• FDA imposed a clinical hold on Rocket’s lead gene therapy program after protocol modifications, delaying key trial milestones.
• Multiple law firms—including Bronstein, Gewirtz & Grossman; Levi & Korsinsky; Pomerantz; Hagens Berman; Rosen Law; Robbins Geller Rudman & Dowd; Faruqi & Faruqi; Gainey McKenna & Egleston—have filed or announced investigations and class action lawsuits against Rocket and its officers for alleged securities fraud.